The current role of model-based drug development

The Use of Clinical Utility Assessments in Early Clinical Development

(2009) Anis A. Khan et al.   AAPS Journal

Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease

(2009) Venkatesh Atul Bhattaram et al.   AAPS Journal

Pharmacometrics-Based Dose Selection of Levofloxacin as a Treatment for Postexposure Inhalational Anthrax in Children

(2009) F. Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

(2009) Johan Gabrielsson et al.   DRUG DISCOVERY TODAY

Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study

(2009) Pravin R. Jadhav et al.   PHARMACEUTICAL STATISTICS

Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development

(2008) Liping Zhang et al.   AAPS Journal

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

(2008) Wendy S. Putnam et al.   AAPS Journal

Quantitative Disease, Drug, and Trial Models

(2008) Jogarao V.S. Gobburu et al.   Annual Review of Pharmacology and Toxicology

Modeling the recurrence–progression process in bladder carcinoma

(2008) Belén García-Mora et al.   COMPUTERS & MATHEMATICS WITH APPLICATIONS

Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004-2006

(2008) Yaning Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis

(2008) Berend Arnold Ploeger et al.   PHARMACEUTICAL STATISTICS